Plain-English translation of NCT05649683 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are testing whether a special blood test can predict how well advanced melanoma patients will respond to a combination immunotherapy using Nivolumab and Ipilimumab. These medications work by helping your immune system fight cancer, but they can also cause serious side effects in some people. This study aims to find blood markers that can tell doctors in advance who will do well on the medication and who might experience complications.
While this combination immunotherapy is effective against advanced melanoma, it can cause severe immune-related side effects in some patients, and doctors currently have no reliable way to predict who will tolerate the treatment well. This study hopes to identify early warning signs in the blood that help balance the medication's benefits against potential harms.
You likely qualify if…
You likely don't qualify if…
You will receive the standard combination immunotherapy as part of your regular cancer care. At the same time, you'll have blood samples drawn at four key timepoints: when you start treatment, at week 6, at week 11 (around your first imaging scan), and if needed, when disease progresses or serious side effects develop. Each visit involves small blood draws that are used to measure immune markers; the entire commitment involves routine clinic visits you'd likely have anyway for your cancer treatment.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
France